A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI

The primary objective of this study is to demonstrate equivalence of pharmacokinetic properties, and comparability of safety and immunogenicity parameters of RPH-030 and Vectibix® following a single (first) intravenous administration to patients with mCRC with wild-type RAS genes as 1-line therapy in combination with FOLFIRI. The additional objective is to perform a pilot evaluation of the efficacy of RPH-030 and Vectibix® following a single (first) intravenous administration to patients with mCRC with wild-type RAS genes as 1-line therapy in combination with FOLFIRI.

Trial Details

NCT ID
NCT07543744
Phase
PHASE1
Sponsor
R-Pharm
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • RPH-030
  • Vectibix®
  • Irinotecan
  • Calcium Folinate
  • Fluorouracil
Locations (sample)
  • Arkhangelsk, Russia|64.5461,40.55183
  • Istra, Russia|55.91979,36.86876
  • Ivanovo, Russia|56.99988,40.97257
  • Kaluga, Russia|54.53063,36.27
  • Kazan', Russia|55.78874,49.12214

Key Eligibility Criteria

  • A voluntarily signed and dated Informed Consent form (ICF) of the patient
  • Histologically verified (documented results of respective examinations available) metastatic colorectal adenocarcinoma (in case the results of prev…
  • Patient consent to undergo a screening biopsy if archival tissue samples are unavailable for histological diagnosis verification
  • Patients with metastatic colorectal cancer (mCRC), either de novo metastatic or recurrent with distant metastases, who are candidates for first-lin…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →